The value of transthoracic contrast echocardiography after pulmonary arteriovenous malformation embolization

The value of transthoracic contrast echocardiography after pulmonary arteriovenous malformation embolization - Value of TTCE after PAVM embolization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51776

Enrollment

100

Registered

2022-07-08

Start date

2023-04-11

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary taemorrhagic telangiectasia (HHT) Rendu-Osler-Weber disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients who underwent embolization for pulmonary arteriovenous malformation and have a follow-up TTCE 6 months after embolization. (restrospective part) Adult patients with a treatable pulmonary arteriovenous malformation who will undergo embolization at the St. Antonius Hospital. (prospective part)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Primary outcomes include: - the pulmonary RLS grade on TTCE: will be determined by the maximum number of microbubbles in the left-sided heart chambers visualized in one frame: 1-30 microbubbles (grade 1), 30-100 microbubbles (grade 2), or >100 microbubbles (grade 3). - the change in echo density on TTCE: will be determined using ImageJ (National Institutes of Health, Bethesda, MA, USA). Three images, two baseline measurements and one frame with the maximum number of microbubbles in the left ventricle, were selected and transported to ImageJ. The average of the two baseline measurements will be calculated, as well as the absolute change in echo density - with the LV baseline considered as darkest possible. A complete white image has a value of 255. The corrected change in echo density will be calculated by dividing the change in ED in the LV (maximum - baseline) by the maximum change possible (255 - baseline). - Presence of macroscopic PAVMs (yes/ no, number), type of PAVMs, presence of reperfusion, recanalization or inadequate embolization, indication for additional treatment on chest CT.	—

Measure

Time frame

Primary outcomes include: - the pulmonary RLS grade on TTCE: will be determined by the maximum number of microbubbles in the left-sided heart chambers visualized in one frame: 1-30 microbubbles (grade 1), 30-100 microbubbles (grade 2), or >100 microbubbles (grade 3). - the change in echo density on TTCE: will be determined using ImageJ (National Institutes of Health, Bethesda, MA, USA). Three images, two baseline measurements and one frame with the maximum number of microbubbles in the left ventricle, were selected and transported to ImageJ. The average of the two baseline measurements will be calculated, as well as the absolute change in echo density - with the LV baseline considered as darkest possible. A complete white image has a value of 255. The corrected change in echo density will be calculated by dividing the change in ED in the LV (maximum - baseline) by the maximum change possible (255 - baseline). - Presence of macroscopic PAVMs (yes/ no, number), type of PAVMs, presence of reperfusion, recanalization or inadequate embolization, indication for additional treatment on chest CT.

—

Secondary

Measure	Time frame
Clinical outcome measures, including: symptoms (dyspnoea, haemoptysis, migraine), complications (cerebral infarction, cerebral abscess, transient ischemic attack), and oxygen saturation - for the description of the study population.	—

Countries

Netherlands

Outcome results